Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccines

NCT01905215 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

128

Enrollment

INDUSTRY

Sponsor class

Conditions

Infections, Respiratory Syncytial Virus

Interventions

BIOLOGICAL: RSV vaccine GSK3003892A (formulation 1)
BIOLOGICAL: RSV vaccine GSK3003893A (formulation 2)
BIOLOGICAL: RSV vaccine GSK3003895A (formulation 3)
BIOLOGICAL: RSV vaccine GSK3003896A (formulation 4)
BIOLOGICAL: RSV vaccine GSK3003898A (formulation 5)
BIOLOGICAL: RSV vaccine GSK3003899A (formulation 6)
DRUG: Placebo comparator

Sponsor

GlaxoSmithKline